ライフサイエンスコーパス: cotreatment

1 cumulation that may be caused by bevacizumab cotreatment.

2 induced apoptosis similar to AZD8055/ABT-737 cotreatment.

3 els; these increases were inhibited by MG132 cotreatment.

4 FN-gamma-inducible protein decreased by Alum cotreatment.

5 trisphosphate (IP3) pool after 6 h butyrate cotreatment.

6 as blocked by desferrioxamine or antioxidant cotreatment.

7 an effect that was blocked by mevalonic acid cotreatment.

8 e therapeutic index of doxorubicin with C646 cotreatment.

9 gene expression observed only upon FICZ/UVA cotreatment.

10 -mediated gene silencing requires paclitaxel cotreatment.

11 tive DNA lesions suppressible by antioxidant cotreatment.

12 along with PEG-leptin and exendin-4 or FGF21 cotreatment.

13 hout mitochondria-targeted antioxidant (MTA) cotreatment.

14 improvements were not affected by furosemide cotreatment.

15 se changes were not attenuated by furosemide cotreatment.

16 rom undergoing apoptosis in response to drug cotreatments.

17 t (ALDOST) by using several interventions as cotreatment: a Mg2+-supplemented diet; amlodipine, a CCB

18 IFN-gamma+TNF-alpha cotreatment activated PKR, resulting in phosphorylation

19 itiation (74.2%) or who started tuberculosis cotreatment after ART initiation (51.6%; P < .001).

20 TCDD cotreatment also reduced EE-mediated stromal edema, hype

21 This cotreatment also results in larger improvements in syste

22 The DMF cotreatment ameliorated CsA-induced renal dysfunction as

23 using an alkaline comet assay (+/-z-VAD-fmk cotreatment) and by levels of iododeoxyuridine-DNA incor

24 and CD8+ alphabeta T cells after HMBPP/IL-2 cotreatment as well as substantial perforin expression b

25 94.8%) than were children who were receiving cotreatment at ART initiation (74.2%) or who started tub

26 Spiro cotreatment attenuated (P<0.05) urinary and fecal Ca2+ a

27 Moreover, Src/Chk1-inhibitor cotreatment attenuated MM-cell production of vascular en

28 Proteasome inhibitor cotreatment blocked the induction of alpha-SMA mRNA, the

29 human epidermal tissue reconstruct, FICZ/UVA cotreatment caused pronounced phototoxicity inducing ker

30 DHA and butyrate cotreatment compared with untreated cells increased the

31 hin ovaries was achieved during chemotherapy cotreatment, concomitant with preservation of primordial

32 number, LC3II, and SQSTM1 accumulation; Tat cotreatment diminished this effect.

33 accumulated in the lung following HMBPP/IL-2 cotreatment displayed an effector memory phenotype, as f

34 HMBPP/IL-2 cotreatment during acute SHIV infection did not prevent

35 In contrast, HMBPP/IL-2 cotreatment during chronic infection did not exacerbate

36 nic loads were not increased upon HMBPP/IL-2 cotreatment during chronic SHIV infection, HMBPP activat

37 M to 0.55 muM; SI-MTT = 70.12 to >357.14) or cotreatment (EC(50) = 34.69 nM to 7.52 muM; SI-MTT = 5.2

38 in other contexts, it may prove useful as a cotreatment for augmenting tumor Ag expression during im

39 Cotreatment for tuberculosis reduced viral suppression.

40 lity, reduced metabolic toxicity, simplified cotreatment for tuberculosis, and preservation of second

41 2272 (about 10-fold versus about 2-fold) and cotreatment had a synergistic effect, increasing cyclic

42 OS cotreatment in both chambers facilitated AECs' transitio

43 apoptosis and cytotoxicity after 24 hours of cotreatment in cell lines and in fresh myeloma cells, an

44 d PIT1 silencing and were mitigated by FGF23 cotreatment in HAoSMCs.

45 d genes were significantly modulated by TCDD cotreatment, indicating a gene-specific inhibitory respo

46 mostly prevented by N-acetyl cysteine (NAC) cotreatment, indicating a major role of oxidative stress

47 In A549 xenografts, brusatol and cisplatin cotreatment induced apoptosis, reduced cell proliferatio

48 The cotreatment induced autophagy (AMPK activation) and impa

49 rylation of IGF-I receptor (IGF-IR), whereas cotreatment induced synergistic phosphorylation and asso

50 Cotreatment-induced apoptosis was accompanied by enhance

51 us underscoring the critical role of RIP1 in cotreatment-induced apoptosis.

52 TCDD cotreatment inhibited EE-induced uterine wet weight by 3

53 Furthermore, IL1Ra/anakinra cotreatment inhibited ricin-mediated inflammatory respon

54 Surprisingly, we find that rapamycin cotreatment inhibits 6-TG-induced autophagy in MMR-profi

55 O(2) following hydrogenation and nitridation cotreatment is significantly higher than that of the sam

56 Importantly, BV6/dexamethasone cotreatment is significantly more effective than monothe

57 ned IRAK1 and BCL2 inhibitors and found that cotreatment more effectively eliminated MDS clones.

58 ath that was reduced to 19.87 +/- 3.03% with cotreatment of 250 nM MK-801.

59 Sepsis with cotreatment of antibiotics and antisense oligonucleotide

60 Sepsis with cotreatment of antibiotics and mismatch oligonucleotides

61 Cotreatment of BEZ235 with DOX resulted in dose-dependen

62 PGE(2), production, was potentiated with the cotreatment of BMDM with H(2)O(2).

63 Interestingly, cotreatment of BMPCs or cell lines with DSB/R inhibitors

64 Cotreatment of bone marrow B cells with 15d-PGJ(2) and M

65 Cotreatment of BRAF-mutated melanoma cell lines with phe

66 Cotreatment of breast cancer cell lines with HDAC inhibi

67 Cotreatment of C57BL/6 with AQ and anti-CTLA4 also resul

68 orylation, and CB1 internalization following cotreatment of CB1 agonist and D2 antagonist were quanti

69 Cotreatment of cells with a selective PPARgamma antagoni

70 d dephosphorylation of IRS-2 is prevented by cotreatment of cells with insulin, (Q3A4Y15L16) IGF-I, o

71 reshly isolated breast cancer cells, whereas cotreatment of cells with tamoxifen or a small molecule

72 Notably, cotreatment of chemotherapeutic agent camptothecin enhan

73 Cotreatment of DEX with D3 or PTH increased gene encodin

74 2-M and augments cell cycle dysregulation on cotreatment of doxorubicin and caffeine.

75 Our findings indicated that cotreatment of drug-resistant neuroblastoma cells with d

76 The cotreatment of EMD with the proteasome inhibitor MG132 r

77 Remarkably, cotreatment of endothelial cells with simvastatin, a hyd

78 We found that IL-4 and retinoic acid (RA) cotreatment of GM-CSF-differentiated IDCs synergisticall

79 RBV cotreatment of HCV-infection improved pSTAT4-dependent I

80 Cotreatment of hepa1c1c7 cells with 2,3,7,8-tetrachlorod

81 id, that is further activated as verified by cotreatment of HepG2 cell lysates with (2E)-hexadecenal

82 Cotreatment of HepG2 cells with 4-HNE and the phosphatid

83 Cotreatment of Jurkat cells with marginally toxic concen

84 Cotreatment of K562 or LAMA cells with subtoxic or margi

85 milarly, in a xenograft model the preemptive cotreatment of lung tumor cells with an EGFR inhibitor a

86 essed the synergistic cytotoxicity seen with cotreatment of luteolin and TNF.

87 Our data show that cotreatment of M. tuberculosis infected rabbits with the

88 Cotreatment of melanomas with BRAF inhibitors and obatoc

89 Cotreatment of melanomas with DCA and elesclomol in vivo

90 Cotreatment of MPA with IFN-alpha resulted in additive e

91 Cotreatment of nonprimed macrophages with ATP and calciu

92 Cotreatment of PD-1(-/-) mice with anti-CTLA4 antibody a

93 In vitro cotreatment of PROM1-expressing Mat1a-/- hepatic progeni

94 Cotreatment of rats with lipopolysaccharide from the pho

95 ction of CYP1A1 and CYP1B1 was observed with cotreatment of SRM 1649a and BP.

96 ween CB1 and D2L were observed using BRET(2) Cotreatment of STHdh(Q7/Q7) cells with ACEA and haloperi

97 cular region of the hypocotyl in response to cotreatment of Suc and sulfonamide, yet no change in aux

98 Cotreatment of T cells with N-acetylcysteine and BSO fai

99 Cotreatment of these cAMP-PDE inhibitors in naive mice w

100 Cotreatment of these mice with ultra-low-dose naltrexone

101 itro analyses: TMZ + p53 inhibitor precursor cotreatment of three distinct p53(wt) GBM xenografts res

102 fect involving hydrogenation and nitridation cotreatment of TiO(2) nanowire (NW) arrays that improves

103 and reactivation of apoptosis in vivo after cotreatment of TNF with a V-ATPase inhibitor.

104 same as those used in HIV-negative patients, cotreatment of tuberculosis with antiretroviral therapy

105 Cotreatment of VPA with 5-azaC in cells almost completel

106 Ps are likely to cooccur at infection sites, cotreatments of cellobiose with flg22 or chitooligomers

107 the synergistic effects of IFN-gamma and MDP cotreatment on adhering and infiltrating cells.

108 ergistic activity of cetuximab and erlotinib cotreatment on growth inhibition of colon cancer cell li

109 sm of action, the effect of DHA and butyrate cotreatment on intracellular Ca2+ homeostasis was examin

110 RA; however, TLR4 activation was affected by cotreatment only.

111 ACEA and haloperidol cotreatments produced a delayed and sustained increase i

112 ) under these conditions, SAHA and cisplatin cotreatment promoted focal accumulation of the low-fidel

113 reconditioned group with PVE and CD133+ BMSC cotreatment (PVE+SC group, n = 11) and a group pretreate

114 ulinization of behavior by ACPD plus kainate cotreatment; rather, the coadministration of NBQX plus L

115 pression seen in MiaPaca2 cells, BEZ and DOX cotreatment reduced BIM expression in H9C2 cardiomyocyte

116 rise in plasma potassium induced by CA, Ucn2 cotreatment reduced potassium concentrations.

117 Cotreatment reduced tumor burden and improved survival.

118 Ucn2 cotreatment reversed CA-induced rises in circulating ald

119 el thromboembolic stroke model in mice, this cotreatment significantly improved ischemic lesion size

120 Moreover, BEZ cotreatment significantly improved the effects of DOX to

121 PD98059 cotreatment significantly inhibited SDF-1alpha-induced N

122 or cancer cell survival and identifies novel cotreatment strategies to override this survival advanta

123 These findings reveal a novel cotreatment strategy for tumors displaying mesenchymal f

124 iver injury induced by polyI:C/posthalothane cotreatment, suggesting that the increased hepatocyte ap

125 as well as survival analysis (P < 0.001 for cotreatment survival benefit in each case).

126 nterestingly, we found that leptin and IGF-I cotreatment synergistically transactivated epidermal gro

127 Remarkably, these cotreatments synergistically triggered mono-ubiquitinati

128 est that calcitonin could be used as a novel cotreatment to augment efficacy and reduce side effects

129 ponse, particularly in settings of sorafenib cotreatment to enhance anticancer responses.

130 induced EGFR downregulation when PRL and EGF cotreatment was compared to EGF treatment alone.

131 ubstantial disruption of neuronal processes; cotreatment with (+)-PTZ revealed marked preservation of

132 Cotreatment with 17-AAG and PKC412 markedly down-regulat

133 Cotreatment with 17-AAG and SAHA also induced down-regul

134 Cotreatment with 17-AAG and SAHA or SB synergistically i

135 Cotreatment with 17-AAG and siRNA to HDAC6 induced more

136 In addition, cotreatment with 17-AAG and tubacin augmented the loss o

137 to at least 24 h and is further decreased by cotreatment with 2-methylthio-ATP.

138 for 1 hour with (+)-PTZ followed by 18-hour cotreatment with 25 microM Glu and (+)-PTZ showed a mark

139 ce was also potentiated in nonmutant mice by cotreatment with a 5-HTT antagonist.

140 Cotreatment with a beta2-adrenergic receptor antagonist,

141 ect of chronic C3 exposure can be blocked by cotreatment with a C3aR antagonist and by genetic deleti

142 Cotreatment with a canonical Wnt signaling inhibitor att

143 antigens were significantly decreased after cotreatment with a caspase inhibitor (P<0.05) and were a

144 Cotreatment with a histone deacetylase inhibitor (an ind

145 of both uptake and biosynthesis pathways by cotreatment with a liver X receptor agonist further augm

146 Cotreatment with a low subanalgesic dose of kelatorphan,

147 imicrobial effect of MSC EV was abrogated by cotreatment with a LTB(4) BLT1 antagonist.

148 nografts highly amenable to sensitization by cotreatment with a miR-139-5p mimetic.Significance: The

149 Cotreatment with a panel of Ca2+-modulating agents ident

150 Since cotreatment with a PPARbeta/delta ligand and various mit

151 to be Top2beta-dependent and preventable by cotreatment with a proteasome inhibitor, suggesting the

152 this decrease could be partially rescued by cotreatment with a proteasome inhibitor.

153 alpha can be switched to apoptosis either by cotreatment with a protein synthesis inhibitor, cyclohex

154 Cotreatment with a retinoid X receptor alpha ligand, 9-c

155 Neuroprotection was abrogated upon cotreatment with a sGC inhibitor, ODQ, thus supporting a

156 either dominant-negative mutant (DN-JNK) or cotreatment with a specific JNK inhibitor SP600125, abro

157 es were added into the media without or with cotreatment with Abeta12-28P, which is a nontoxic peptid

158 Cotreatment with ACE-536 and EPO produced a synergistic

159 Cotreatment with agents that elevate cAMP in BCECs preve

160 As compared with either agent alone, cotreatment with AMN107 and LBH589 induced more loss of

161 ells to panobinostat as well as suggest that cotreatment with an anti-Bcl-2 agent would augment the a

162 Therefore, cotreatment with an AR antagonist, bicalutamide, blocked

163 Cotreatment with an estrogen receptor (ER) antagonist in

164 Cotreatment with an inhibitor of peroxisome proliferator

165 Ucn2 cotreatment with an MRA in HF further improved hemodynam

166 In fact, cotreatment with an NO-peroxynitrite scavenger revealed

167 ti-CD4 mAb-induced apoptosis is inhibited by cotreatment with anti-CD8 mAb and responsiveness to irre

168 ddition of cytokines or growth factors or by cotreatment with antiandrogens.

169 ocytosis of TCL cells, which was enhanced by cotreatment with antibodies targeting MHC class I.

170 in sodium intake, the effect of differential cotreatment with antihypertensive medications, and long

171 tential (MMP) in Panc1 and L3.6pL cells, and cotreatment with antioxidants (glutathione and dithiothr

172 duce reactive oxygen species generation, and cotreatment with antioxidants did not alter erlotinib-in

173 e hallmark symptoms of B12/FA deficiency and cotreatment with aryl hydrocarbon portions of B12/FA res

174 Cotreatment with ascorbate and JQ1 induced apoptosis and

175 However, cotreatment with ATRA reduces Bcl6 expression to baselin

176 ous atRA concentrations and may be useful as cotreatment with atRA to combat therapy resistance.

177 e cytokine release was inhibited by pre- and cotreatment with ATRA; however, TLR4 activation was affe

178 Compared with each agent alone, cotreatment with BA and ibrutinib markedly improved the

179 Cotreatment with BA and panobinostat (pan-histone deacet

180 Cotreatment with BA and the BTK inhibitor ibrutinib syne

181 Cotreatment with BH4 prevented NOS3 uncoupling and inhib

182 Cotreatment with both agents increased the number of tra

183 Cotreatment with BT-11 and IL-2 greatly enhances the dif

184 ing SC104 treatment of colorectal cells, and cotreatment with caspase inhibitors has been shown to in

185 n bone metastasis and bone loss, and suggest cotreatment with CCL3, beta-catenin inhibitors, anti-RAN

186 bility, and activation of apoptosis, whereas cotreatment with chloroquine or knockdown of Atg7, but n

187 These effects can be prevented by cotreatment with cholesterol and sphingomyelin, and can

188 Cotreatment with CHX and TCDD caused superinduction of C

189 ed hepatoma 1c1c7 cultures was suppressed by cotreatment with CHX.

190 Finally, cotreatment with clenbuterol and recombinant human IGF1

191 +) and CD8(+) T cells that was reversed upon cotreatment with CTLA-4-Ig.

192 K1/2 in AML cells, which was not affected by cotreatment with CXCL12.

193 RBV cotreatment with DAA-therapy for HCV increased CD56Brigh

194 Importantly, cotreatment with dexamethasone (Dex) could not efficient

195 in GC-resistant T-ALL cells, and remarkably, cotreatment with dexamethasone is able to reverse GC res

196 reased PARP activity in thymus and liver, as cotreatment with dioxin and the PARP inhibitor PJ34 incr

197 Furthermore, cotreatment with DNA replication inhibitor aphidicolin a

198 ts that the oxazolidine forms in situ, since cotreatment with doxorubicin and formaldehyde is highly

199 he lead molecule in the sulfamide series, in cotreatment with doxorubicin, demonstrated a chemosensit

200 mpared with treatment with each agent alone, cotreatment with DZNep and the pan-histone deacetylase i

201 Cotreatment with either fulvestrant or anastrazole compl

202 he loss of CYP3A4 protein was accelerated by cotreatment with either proteasome or NF-kappaB inhibito

203 nucleus without endosomal entrapment because cotreatment with endosome-disrupting agent had no effect

204 Cotreatment with epigenetic-modulating drugs and checkpo

205 We hypothesized that cotreatment with everolimus may improve the efficacy of

206 combined inhibitors and largely prevented by cotreatment with exogenous polyamines.

207 rotic populations compared to control, while cotreatment with ferrostatin-1 (Fer-1) completely revert

208 d interleukin-8 protein detectable following cotreatment with flagellin and Stx2.

209 d resistance to apoptosis can be overcome by cotreatment with Flavopiridol, which promotes survivin d

210 ShPTEN gland development were attenuated by cotreatment with GW9662, a PPARgamma antagonist.

211 This adaptation was prevented by cotreatment with hormone therapies or PI3K inhibitors, w

212 rantly overexpress functional ABCG2 but that cotreatment with IM and an ABCG2 inhibitor does not pote

213 However, cotreatment with inhibitors of mitochondrial oxidative p

214 Notably, cotreatment with inhibitors of the proteasome or the cyc

215 isomycin-induced amnesia was abolished after cotreatment with JNKs selective inhibitor sp600125 witho

216 C57BL/6 mice, effects that were reversed by cotreatment with JQ1.

217 Cotreatment with KNK437, a benzylidine lactam inhibitor

218 rted by Bcl-2 overexpression was reversed by cotreatment with LAQ824 and Apo-2L/TRAIL.

219 Significantly, cotreatment with LAQ824 increased Apo-2L/TRAIL-induced a

220 Finally, cotreatment with LBH589 and 17-AAG also induced more apo

221 Cotreatment with LBH589 and 17-AAG exerted synergistic a

222 Cotreatment with LBH589 and AMN107 exerted synergistic a

223 Thus, cotreatment with LBH589 and AMN107 is active against cul

224 In the present study, we show that cotreatment with leptin and IGF-I significantly increase

225 f this tolerant state by ECP was obviated by cotreatment with lipopolysaccharide, suggesting that the

226 ion of 1alpha,25(OH)2D3 can be 'restored' by cotreatment with low doses of HDAC inhibitors such as tr

227 ith a cytokine mixture (CM) was augmented by cotreatment with low-dose Tr-OxPLs, which did not signif

228 acellular permeability, which was blocked by cotreatment with LPA, but not LPA1 knockdown cells.

229 Cotreatment with MEK1/2 inhibitors increased the associa

230 Lovastatin-induced effects were reversed by cotreatment with mevalonolactone or geranylgeranyl-pyrop

231 otoxicity of TCL cells that was augmented by cotreatment with mogamulizumab, an anti-CCR4 mAb, or a m

232 red with all other treatment groups, whereas cotreatment with mTOR inhibitors preserved normal fertil

233 Destabilization of this conformation by cotreatment with muOR and deltaOR ligands leads to a swi

234 ytes, an effect that could be antagonized by cotreatment with muscarine.

235 Cotreatment with N-benzoyloxycarbonyl-(Z)-Leu-Leu-leucin

236 reduced with BSO treatment and restored with cotreatment with NAC or l-cysteine.

237 R1 expression (P<0.05), which was negated by cotreatment with nAChRalpha-7 antagonist.

238 Moreover, under basal conditions, cotreatment with PF-04957325 plus rolipram, a PDE4-selec

239 In contrast, cotreatment with phenformin, an inhibitor of complex I o

240 o short-term NMBA treatment and modulated by cotreatment with phenylethyl isothiocyanate (PEITC).

241 y arise in the clinic yet can be overcome by cotreatment with PI3K/AKT inhibitors.

242 l hai1a amorphs are efficiently rescued upon cotreatment with PLD inhibitors and S1P.

243 Cotreatment with previously identified ellipticine and p

244 However, cotreatment with proteasome inhibitors fully restores th

245 Compared with each agent alone, cotreatment with PS and CXCR4 antagonist AMD3100 or FC-1

246 Cotreatment with PS and TG101209 further depleted JAK/ST

247 e association of eIF-4E with eIF-4G, whereas cotreatment with purvalanol A inhibited the association

248 rin in the podocytes, which was prevented by cotreatment with pyrintegrin.

249 RA alone had no effect on p53-NRD activity, cotreatment with RA and the histone deacetylase inhibito

250 Cotreatment with rapamycin and trichothecenes reduced RO

251 Treatment with VEGF and cotreatment with Rb1 and VEGF showed that this Rb1-induc

252 Cotreatment with selective blockers of L-, N-, and P/Q-t

253 Cotreatment with sildenafil enhanced DOX-induced apoptos

254 owever, tumor growth was markedly reduced by cotreatment with sorafenib and adenoviral vectors encodi

255 Cotreatment with specific P-gp inhibitor PSC833 reversed

256 Cotreatment with Stx2 and flagellin results in a synergi

257 Cotreatment with TG101209 and PS exerted greater cytotox

258 BRCA-1 transcription are counteracted by (a) cotreatment with the AhR antagonist 3'-methoxy-4'-nitrof

259 These effects were reversed by cotreatment with the Akt inhibitors perifosine and GSK69

260 in II-induced hypertension was attenuated by cotreatment with the alphaAnalogue (50 nmol.kg(-1).d(-1)

261 These IGF-1 actions, which may be blocked by cotreatment with the anti-IGF-1 antibody, were accompani

262 bacterial CDDL expression, and abrogated by cotreatment with the antibiotic ciprofloxacin.

263 e effects are significantly attenuated after cotreatment with the antioxidant GSH.

264 Cotreatment with the autophagy inhibitor chloroquine blo

265 Accordingly, cotreatment with the autophagy inhibitor chloroquine inc

266 Cotreatment with the Bcl-2/Bcl-x(L) antagonist ABT-737 d

267 Cotreatment with the BMP antagonist noggin or the NADPH

268 Cotreatment with the BMP-2 antagonist DMH1 limits, but d

269 Cotreatment with the caspase-3 inhibitor Z-VAD-FMK abrog

270 uamous cell carcinoma in a mouse model using cotreatment with the compound and the carcinogen.

271 Cotreatment with the diuretic furosemide in wild-type mi

272 was independent of CYP3A4 and was negated by cotreatment with the drug efflux transporter inhibitor e

273 Cotreatment with the ER antagonist tamoxifen completely

274 Cotreatment with the GLP-1 receptor agonist exendin-4 re

275 R2(+) cells, knockdown of HER3 with siRNA or cotreatment with the HER2 inhibitors trastuzumab or lapa

276 t the antitumor effects of AT are blocked by cotreatment with the HMG-CoA reductase product mevalonat

277 ent hepatocytes incubated with omega-3 PUFA, cotreatment with the iron chelator desferrioxamine, an i

278 ith elevated OxPhos could be resensitized by cotreatment with the mTORC1/2 inhibitor AZD8055, whereas

279 vo and that this effect could be reversed by cotreatment with the OAT6 inhibitor probenecid.

280 2AX after DHODH inhibition is preventable by cotreatment with the pan-caspase inhibitor Z-VAD-FMK.

281 nists was significantly down-regulated after cotreatment with the PPARgamma antagonist GW9662.

282 Furthermore, cotreatment with the proteasome inhibitor N-benzoyloxyca

283 Cotreatment with the prototypical pregnane X receptor ac

284 s, which could not, however, be prevented by cotreatment with the selective CypD inhibitor, Debio 025

285 This protection was abolished by cotreatment with the SERCA inhibitor cyclopiazonic acid.

286 Cotreatment with the Src-family kinase inhibitor PP2 pre

287 Moreover, skin inflammation was reduced by cotreatment with the TNFalpha signaling inhibitor, etane

288 Cotreatment with these interventions either markedly att

289 and malignant cell death can be achieved by cotreatment with TNF-alpha and a mimetic of second mitoc

290 Cotreatment with TNF-alpha augmented the formation and a

291 Cotreatment with tPA resulted in greater intratumoral pe

292 e non-narcotic clinical analgesics utilizing cotreatment with ultra-low-dose rolipram plus ultra-low-

293 The effects of cotreatment with various concentrations of SA and JA wer

294 Cotreatment with VEGF-trap completely sequestered free V

295 f 1-analogues is likely MDR-mediated because cotreatment with verapamil, a P-gp inhibitor, partially

296 A cotreatment with vitamin C (1 mM) efficiently inhibited

297 ency was effectively reduced consequent to a cotreatment with vitamin C.

298 In cotreatments with IFNgamma, DIM produced an additive act

299 Pretreatment, but not cotreatment, with interferon attenuators valproate, Jak1

300 sfer of EphA2-specific CD8+ T cells, 17-DMAG cotreatment yielded a superior tumor therapeutic regimen